The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial
Open accessAbstract
Summary Background Spinal and bulbar muscular atrophy (SBMA) is caused by polyglutamine expansion in the androgen receptor, which results in ligand-dependent toxicity. Animal models have a neuromuscular deficit that is mitigated by androgen-reducing treatment. Methods We explored the efficacy and safety of the 5-alpha-reductase inhibitor, dutasteride, in a single-site, two-year, double-blind, placebo-controlled clinical trial. Physical, neurophysiological, quality of life, and biochemical outcomes were assessed in 50 ambulatory, symptomatic, genetically confirmed, male SBMA subjects randomised to receive dutasteride or placebo (25 in each group). Findings At 24 months, the placebo group showed a decrease of 5% (−0.30 kg/kg) in the primary outcome measure, change in weight-scaled muscle strength as indicated by quantitative muscle assessment (QMA), and the dutasteride group showed an increase in strength of 1% (+0.14 kg/kg); the difference between the groups (6%; CI 18%, −6%) was not significant. Secondary measures of creatine kinase, muscle strength and function, motor and sensory nerve conduction, activities of daily living, and erectile function did not show a significant difference between the study groups in change from baseline. However, quality of life as measured by the SF-36v2 physical component summary favored dutasteride, while the mental component summary favored placebo. The dutasteride group had fewer falls; there were no other significant differences in reported adverse events. Interpretation This study did not show a significant effect of dutasteride on the progression of muscle weakness in SBMA, although there were secondary indications of benefit. A longer trial duration or larger number of subjects may be needed to show an effect on the disease progression. Performance testing, QMA, and quality of life measures were identified as potentially useful endpoints for future therapeutic trials. Funding National Institutes of Health
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.
Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., & Russell, D. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116665 · Cited by 727
Cited by
SIRT1 in Neurodevelopment and Brain Senescence
Herskovits, A. Z., & Guarente, L. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.028 · Cited by 488
Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases
Takeuchi, T., & Nagai, Y. (2017) · Brain Sciences · doi:10.3390/brainsci7100128 · Cited by 71
Nemo-like kinase is a novel regulator of spinal and bulbar muscular atrophy
Todd, T. W., Kokubu, H., Miranda, H. C., Cortes, C. J., La Spada, A. R., & Lim, J. (2015) · eLife · doi:10.7554/elife.08493 · Cited by 21
Hijikata, Y., Katsuno, M., Suzuki, K., Hashizume, A., Araki, A., Yamada, S., Inagaki, T., Ito, D., Hirakawa, A., Kinoshita, F., et al. (2018) · JMIR Research Protocols · doi:10.2196/resprot.8655 · Cited by 13
Metadata
- Authors
- Fernández-Rhodes, L. E., Kokkinis, A. D., White, M. J., Watts, C. A., Auh, S., Jeffries, N. O., Shrader, J. A., Lehky, T. J., Li, L., Ryder, J. E., Levy, E. W., Solomon, B. I., Harris-Love, M. O., La Pean, A., Schindler, A. B., Chen, C., Di Prospero, N. A., & Fischbeck, K. H.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2011-02
- Volume
- 10
- Issue
- 2
- Pages
- 140-147
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2133563625
- Cited by
- 159
- References
- 1
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s1474-4422(10)70321-5
- The paper
- Fernández-Rhodes, L. E., Kokkinis, A. D., White, M. J., Watts, C. A., Auh, S., Jeffries, N. O., Shrader, J. A., Lehky, T. J., Li, L., Ryder, J. E., Levy, E. W., Solomon, B. I., Harris-Love, M. O., La Pean, A., Schindler, A. B., Chen, C., Di Prospero, N. A., & Fischbeck, K. H. (2011). Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(10)70321-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.